ERNAW Ernexa Therapeutics Inc.: institutional ownership and insider trading
6 funds reported holding $202K of Ernexa Therapeutics Inc. in their latest 13F filings; in Q2 2026 funds net sold $283K, with 1 new positions and 0 funds selling out; over the last 12 months insiders bought $2.00M and sold $0 on the open market.
ERNAW revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$4.01M, EPS -3.40
- Quarter ended Mar 31, 2026: revenue n/a, net income −$5.51M, EPS -6.95
- Quarter ended Dec 31, 2025: revenue n/a, net income −$1.50M, EPS 70.86
- Quarter ended Sep 30, 2025: revenue n/a, net income −$1.24M, EPS -0.15
Largest institutional holders of ERNAW
- Bleichroeder LP — $143K
- HEIGHTS CAPITAL MANAGEMENT, INC — $28.5K
- ARMISTICE CAPITAL, LLC — $11.4K
- Clear Street Group Inc. — $10.7K
- Warberg Asset Management LLC — $4.95K
- SUSQUEHANNA INTERNATIONAL GROUP, LLP — $4.13K
Recent ERNAW insider trades
- Feb 10, 2026: Cherington Charles bought 4,000,000 shares ($2.00M)
- Jun 9, 2025: Cherington Charles bought 21,241,163 shares ($2.12M)
- Apr 2, 2025: Cherington Charles bought 3,768,397 shares ($377K)
5%+ owners
- Charles Cherington: 34.7% (Schedule 13D/A, filed Feb 17, 2026)
- Freebird Partners LP: 9.9% (Schedule 13G/A, filed May 15, 2026)
- Shameek Konar: 9.7% (Schedule 13G/A, filed May 13, 2026)
- Bleichroeder LP: 6.9% (Schedule 13G, filed May 14, 2026)
- John D. Halpern: 5.6% (Schedule 13G/A, filed May 15, 2026)
Who owns the most ERNAW stock?
The largest institutional holders of Ernexa Therapeutics Inc. in the latest 13F filings are Bleichroeder LP ($143K), HEIGHTS CAPITAL MANAGEMENT, INC ($28.5K), ARMISTICE CAPITAL, LLC ($11.4K).
Are insiders buying or selling ERNAW?
Over the last 12 months insiders bought $2.00M and sold $0 of Ernexa Therapeutics Inc. stock on the open market (SEC Form 4).